Potential of [C-11](R)-PK11195 PET Imaging for Evaluating Tumor Inflammation: A Murine Mammary Tumor Model

Imagem de Miniatura
Arquivos
art_SOUZA_Potential_of_C11RPK11195_PET_Imaging_for_Evaluating_Tumor_2022.PDF (3.62 MB)
Citações na Scopus
1
Tipo de produção
article
Data de publicação
2022
DOI
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Editora
MDPI
Autores
Citação
PHARMACEUTICS, v.14, n.12, article ID 2715, 14p, 2022
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Background: Breast tumor inflammation is an immunological process that occurs mainly by mediation of Tumor-Associated Macrophages (TAM). Aiming for a specific measurement of tumor inflammation, the current study evaluated the potential of Positron Emission Tomography (PET) imaging with [C-11](R)-PK11195 to evaluate tumor inflammation in a mammary tumor animal model. Methods: Female Balb/C mice were inoculated with 4T1 cells. The PET imaging with [C-11](R)-PK11195 and [F-18]FDG was acquired 3 days, 1 week, and 2 weeks after cell inoculation. Results: The [C-11](R)-PK11195 tumor uptake increased from 3 days to 1 week, and decreased at 2 weeks after cell inoculation, as opposed to the [F-18]FDG uptake, which showed a slight decrease in uptake at 1 week and increased uptake at 2 weeks. In the control group, no significant differences occurred in tracer uptake over time. Tumor uptake of both radiopharmaceuticals is more expressed in tumor edge regions, with greater intensity at 2 weeks, as demonstrated by [C-11](R)-PK11195 autoradiography and immunofluorescence with TSPO antibodies and CD86 pro-inflammatory phenotype. Conclusion: The [C-11](R)-PK11195 was able to identify heterogeneous tumor inflammation in a murine model of breast cancer and the uptake varied according to tumor size. Together with the glycolytic marker [F-18]FDG, molecular imaging with [C-11](R)-PK11195 may provide a better characterization of inflammatory responses in cancer.
Palavras-chave
[C-11](R)-PK11195, TSPO, macrophages, positron emission tomography, breast cancer, inflammation
URI
https://observatorio.fm.usp.br/handle/OPI/51668
Referências
  1. Alcantara D, 2014, FRONT CHEM, V2, DOI 10.3389/fchem.2014.00112
  2. Ashton TM, 2018, CLIN CANCER RES, V24, P2482, DOI 10.1158/1078-0432.CCR-17-3070
  3. Bhoola NH, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19082176
  4. Bogdanovic RM, 2014, NEUROPHARMACOLOGY, V85, P104, DOI 10.1016/j.neuropharm.2014.05.002
  5. BRAESTRUP C, 1977, P NATL ACAD SCI USA, V74, P3805, DOI 10.1073/pnas.74.9.3805
  6. Chauveau F, 2008, EUR J NUCL MED MOL I, V35, P2304, DOI 10.1007/s00259-008-0908-9
  7. Faria DD, 2014, J NEUROIMMUNE PHARM, V9, P468, DOI 10.1007/s11481-014-9544-2
  8. Gaemperli O, 2012, EUR HEART J, V33, P1902, DOI 10.1093/eurheartj/ehr367
  9. Gao ZW, 2021, J PHARMACOL SCI, V145, P115, DOI 10.1016/j.jphs.2020.10.004
  10. Gavish M, 1999, PHARMACOL REV, V51, P629
  11. Hasnain Nimra, 2020, J Pak Med Assoc, V70, P2291
  12. Kang Y, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0201289
  13. Kang YN, 2018, J NEUROIMAGING, V28, P496, DOI 10.1111/jon.12519
  14. LEFUR G, 1983, LIFE SCI, V32, P1839, DOI 10.1016/0024-3205(83)90062-0
  15. Li J, 2017, BIOCONJUGATE CHEM, V28, P1016, DOI 10.1021/acs.bioconjchem.6b00711
  16. Li XY, 2022, THER ADV MED ONCOL, V14, DOI 10.1177/17588359221076194
  17. Li YC, 2020, ACS APPL BIO MATER, V3, P4335, DOI 10.1021/acsabm.0c00368
  18. Liu TW, 2022, INT J MOL SCI, V23, DOI 10.3390/ijms23084148
  19. Madera L, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0133385
  20. Mantovani A, 2004, TRENDS IMMUNOL, V25, P677, DOI 10.1016/j.it.2004.09.015
  21. Najafi M, 2019, J CELL BIOCHEM, V120, P2756, DOI 10.1002/jcb.27646
  22. Oishi Y, 2018, INT IMMUNOL, V30, P511, DOI 10.1093/intimm/dxy054
  23. Passamonti L, 2018, NEUROLOGY, V90, pE1989, DOI 10.1212/WNL.0000000000005610
  24. Viana CTR, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0130809
  25. Serhan CN, 2011, CURR TOP MED CHEM, V11, P629
  26. Shoshan-Barmatz V, 2010, MOL ASPECTS MED, V31, P227, DOI 10.1016/j.mam.2010.03.002
  27. Singh N, 2019, ANN AFR MED, V18, P121, DOI 10.4103/aam.aam_56_18
  28. Su ZJ, 2013, EUR J NUCL MED MOL I, V40, P1406, DOI 10.1007/s00259-013-2447-2
  29. Sucksdorff M, 2017, J NUCL MED, V58, P1646, DOI 10.2967/jnumed.116.183020
  30. Tortelli TC, 2021, AGING-US, V13, P21914, DOI 10.18632/aging.203528
  31. Waterfield JD, 1999, RHEUMATOLOGY, V38, P1068, DOI 10.1093/rheumatology/38.11.1068
  32. Wu CX, 2014, THERANOSTICS, V4, P546, DOI 10.7150/thno.8159
  33. Wu XT, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0071258
  34. Zinnhardt B, 2020, NEURO-ONCOLOGY, V22, P1030, DOI 10.1093/neuonc/noaa023

Coleções
Artigos e Materiais de Revistas Científicas - FM/Outros
Artigos e Materiais de Revistas Científicas - FM/MDR
Artigos e Materiais de Revistas Científicas - HC/ICESP
Artigos e Materiais de Revistas Científicas - HC/InRad
Artigos e Materiais de Revistas Científicas - LIM/24
Artigos e Materiais de Revistas Científicas - LIM/43
Carregar mais